481 Results (Page 12 of 20)
UK Markets Research Reports
UK Anemia Drugs Market Analysis
The UK Anemia drugs market was valued at $415 Mn in 2022 and is estimated to expand at a CAGR of 6.9% from 2022-30 and will reach $709 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, driving demand for anemia drugs. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pfizer, Roche, Amgen, GlaxoSmithKline, Johnson & Johnson, Alcon Laboratories, FibroGen, Vifor Pharma Group, and Akebia Therapeutics among others.
UK Alexipharmic Drugs Market Analysis
The UK Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 2.70% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The UK Alexipharmic Drugs market will grow because of the increasing burden of chronic diseases and rising healthcare expenditure. The key market players are AstraZeneca, GlaxoSmithKline, Hikma Pharmaceuticals, Mallinckrodt Pharmaceuticals, Shire Pharmaceuticals, BTG International, and others.
UK Biosimilars Market Analysis
The UK biosimilars market size was valued at $0.5 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 20.2% from 2022 to 2030 and will reach $2.1 Bn in 2030. The market is segmented by product type and indication type. The UK Biosimilars market will grow as Biosimilars provide a more affordable alternative to pricey biologic drugs, which can help to reduce healthcare costs for both patients and payers. The key market players are Pfizer, Sandoz, Celltrion, Biogen, Samsung Bioepis, Mylan, and others.
UK Multiple Myeloma Therapeutics Market Analysis
The UK Multiple Myeloma Therapeutics Market was valued at $217 Mn in 2022 and is estimated to expand at a CAGR of 2.5% from 2022 to 2030 and will reach $264 Mn in 2030. One of the main reasons propelling the growth of this Market is increase in chronic disease, aging population. The Market is segmented by type, drug and distribution channel. Some key players in this Market are Takeda, Amgen, Janssen-Cilag, Celgene, AstraZeneca and others.
UK Lung Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the UK Lung Cancer Therapeutics Market will reach a value of $1245 Mn from $775 Mn in 2022, growing at a CAGR of 6.1% during 2022-30. The Lung Cancer Therapeutics Market in the UK is dominated by a few domestic pharmaceutical companies such as Scancell, Sareum Holdings, and AstraZeneca. The Lung Cancer Therapeutics Market in the UK is segmented into different types of cancer and different therapy types. Some of the major factors affecting the UK lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.
UK Diabetes Therapeutics Market Analysis
The UK diabetes therapeutics market is expected to grow from $3.74 Bn in 2022 to $6.77 Bn in 2030 with a CAGR of 7.7% for the forecasted year 2022-30. The rising incidence of diabetes and the subsequent demand for new and innovative treatment options for diabetes in the UK is driving the growth of the market. The UK diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Tanner Pharma, Bracco, and AstraZeneca are the major players in the UK diabetes therapeutics market.
UK Diabetes Devices Market Analysis
The UK Diabetes Devices Market is expected to witness growth from $591 Mn in 2022 to $887 Mn in 2030 with a CAGR of 5.20% for the forecasted year 2022-30. Diabetes is becoming more common in the UK, which is raising the demand for diabetes devices. Continuous glucose monitoring systems and flash glucose monitoring systems are two examples of non-invasive and slightly invasive diabetes devices that are in increasing demand in the UK. The market is segmented by type and by the end user. Some key players in this market include Magstim, Deltex Medical, Johnson & Johnson, Philipps Healthcare, Medtronic, DSM N.V., Roche and Dexcom.
UK Dental Care Market Analysis
The UK dental care market size is at around $933 Mn in 2022 and is projected to reach $1,317 Mn in 2030, exhibiting a CAGR of 4.4% during the forecast period. 18% of the population has experienced one or more of the following oral problems: trouble pronouncing words, difficulty eating, embarrassment, self-consciousness, or terrible hurting in the mouth and 23.4% of 5-year-old children in England had experienced of dental decay. The report by Insights10 is segmented by treatment type, age group, clinical setup and demography and provides in-depth market insights.
UK 3D Imaging Market Analysis
The UK 3D imaging market is projected to grow from $0.79 Bn in 2022 to $2.33 Bn by 2030, registering a CAGR of 14.5% during the forecast period of 2022-30. The market will be driven by technological advancements and government initiatives to promote the same. The market is segmented by product, application, end-user & by portability. Some of the major players include Philips Healthcare, GE Healthcare & Vision RT Ltd.
UK Patient Support Programs (PSP) Market Analysis
The UK Patient Support Programs (PSP) market is expected to grow from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of 7.9% for the year 2022-2030. Rising technological advancements as well as increased investments in the PSP segments by the pharmaceutical companies in the UK are the major drivers of the UK Patient Support Programs (PSP) market. The market is segmented by functionality outlook, therapeutic outlook, application outlook, and end user. Wren Healthcare, Alcura, and Atlantis Healthcare are some of the major operators in the UK Patient Support Programs (PSP) market.
UK Acromegaly Therapeutics Market Analysis
UK Acromegaly Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The prevalence and incidence of acromegaly and pituitary tumours are rising, as is global awareness of the disease. Technological advances in the development of new acromegaly medications are also key contributors to the market's growth. The high prevalence of hormonal problems, evolving lifestyles, and rising genetic disease incidence are all anticipated to fuel market expansion.Some of the key players in the global acromegaly therapeutics Market include Roche, Sanofi, GSK, Pfizer INC., Ipsen, Chiasma Inc, Validus pharmaceuticals LLC., Novartis AG, Amryt, Recordati, Sun Pharma, Crinetics Pharmaceuticals, Camurus, Ionis Pharmaceuticals , and Others.
UK Alport Syndrome Therapeutics Market Analysis
UK during the forecast period of 2023-30, the Alport Syndrome therapeutics market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. Almost always affecting the kidney, Alport syndrome is a multisystem condition that also usually affects the inner ear and the eye. A variety of symptoms that normally start in childhood or adolescence and may get worse over time can be present. Invitae Corporation, Hoffmann-La Roche Ltd., Centogene N.V., and Eurofins Discovery are a few of the leading companies in the worldwide Alport syndrome market.
UK Anal Fistula Therapeutics Market Analysis
UK During the forecast period of 2023?2030, the Anal Fistula Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. A rare intestinal ailment that typically appears following an acute perianal abscess and is defined by improper connection between the lower rectum and the perianal skin. The market is expanding more quickly thanks to technological advancements in anal fistula therapy. The development of novel surgical treatment options and the explosive growth of the medical tourism business have contributed to the sector's segment expansion. The leading companies profiled in the market research study on anal fistula treatment include Becton, Medtronic, Dickinson and Company, Gem Srl, Biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, Pfizer.
UK Angelman Syndrome Therapeutics Market Analysis
UK During the forecast period of 2023?2030, The Angelman Syndrome Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. An uncommon inherited neuro-developmental condition called Angelman Syndrome is marked by a severe developmental delay, sleep issues, jerky movements, and a lot of laughter. As the illness is more common, there are more government measures to manage it. This has also helped with research and development for condition treatment. These factors collectively represent the Angelman Syndrome Therapeutics Market's driving forces. Boston Children's Hospital, the Angelman Syndrome Foundation, Rady Children's Hospital in San Diego, General Hospital Corporation, Cincinnati Children's Hospital Medical Center, and others are major competitors in the market for treating Angelman syndrome.
UK Ankylosing Spondylitis Therapeutics Market Analysis
UK Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.
UK Uveitis Therapeutics Market Analysis
UK Uveitis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Uveitis is an inflammation of the uvea, which is the middle layer of the tissue that surrounds the eye and is made up of the iris, ciliary body, and choroid. The most typical extra-articular Spondyloarthritis symptom is uveitis (SpA) Increased healthcare financing, together with the development of drugs with improved efficacy and fewer side effects, has benefited technological advancements in the field, which together are serving as a potential driver of the uveitis therapeutic market. Several well-known companies involved in the development and marketing of uveitis medicines include Novartis AG, Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Johnson & Johnson, AbbVie Inc., and Allergan (now a division of AbbVie).
UK Anthrax Therapeutics Market Analysis
UK Anthrax therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Bacillus anthracis is the bacteria that causes anthrax (B. anthracis). The market for anthrax therapeutics is fueled by factors such the increased prevalence of bacterial infections, rising research funding, the development of innovative medicines for treating anthrax, and pipeline goods, which increase demand and stimulate market expansion. The current rise in healthcare spending in both developed and developing nations is anticipated to give manufacturers a competitive edge in the development of novel and ground-breaking products. Global industries in the Anthrax therapeutics market are Aristo Pharmaceuticals Private Limited, Indoco Remedies Ltd., Lupin, Deinove, Bayer AG, Pfizer Inc., Emergent, Soligenix, Zydus Group, Sanofi, Alembic Pharmaceuticals, Emergent, Sanofi, Porton Biopharma, Lupin, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd and many more
UK Basal Cell Carcinoma Therapeutics Market Analysis
UK Basal Cell Carcinoma Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The most typical type of skin cancer and the most typical type of cancer overall is basal cell carcinoma (BCC). Rarely can basal cell carcinoma appear in mucous membranes; it typically appears on sun-damaged skin. The market for Basal Cell Carcinoma Therapeutics is being driven by an increase in the occurrence of skin cancers and better treatment options. The high cost of care and basal cell carcinoma's high propensity for underdiagnosis, however, are anticipated to impede the market's expansion. The high cost of care and basal cell carcinoma's high propensity for underdiagnosis, however, are anticipated to impede the market's expansion. Companies like MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma, Epitome Pharmaceuticals, Transgene, Senhwa Biosciences, Palvella Therapeutics, Suzhou Kintor Pharmaceuticals, Leaf Vertical, and others are active in the basal cell carcinoma market.
UK Colorectal Cancer Therapeutics Market Analysis
UK Colorectal Cancer Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Colon cancer, commonly known as colorectal cancer (CRC), is a condition that affects the large intestine. It is a type of cancer that develops in the colon or rectum. The surge in product introductions and colorectal cancer awareness are two factors driving the global market for drugs to treat the disease. The high incidence of colorectal cancer, which contributes to high mortality rates, and the rising global desire for more potent treatments are additional important driving forces. Genentech, Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Sanofi, Merck Sharp & Dohme Corp., Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.), Bayer AG, Regeneron Pharmaceuticals, Inc., Novartis AG, Ipsen Biopharmaceuticals, Inc., and numerous other global companies participate in the colorectal cancer therapeutics
UK Cryptococcosis Therapeutics Market Analysis
UK Cryptococcosis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The pathogenic yeasts in the genus Cryptococcus that cause cryptococcosis have a wide range of clinical manifestations and are contagious throughout the world. Currently, Cryptococcus neoformans and Cryptococcus gattii are the two species of the bacteria most frequently linked to human illness. The market for disorders caused by cryptococcosis is expanding as a result of the rising prevalence of the condition and the availability of cutting-edge treatments. Bristol-Myers Squibb, Abbott Laboratories, Pfizer, Glenmark Pharmaceuticals, Bausch Health, Johnson & Johnson, Novartis AG, Janssen Biotech, Sigmapharm Laboratories, Matinas BioPharma, Mycovia Pharmaceuticals, Aparna Biosciences, FUJIFILM Toyama Chemical, TGV Therapeutics, Amplyx Pharmaceuticals, and many others are leading companies in the global market for Cryptococcosis therapeutics.
UK Cystic Fibrosis (CF) Therapeutics Market Analysis
UK Cystic Fibrosis (CF) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Cystic fibrosis (abbreviated CF) is a genetic disorder that causes mucus to build up in certain organs of the body, particularly the lungs and pancreas, resulting in breathing problems, respiratory infections and faulty digestion. The increasing prevalence of Cystic Fibrosis (CF) coupled with the rising treatment rate is one of the key factors anticipated to propel the demand for cystic fibrosis therapeutics over the forecast period. The key players are consistently involved in the development of new or combination of products to treat cystic fibrosis. Investment in the R&D is one of the strategic measures to beat the competition. The key players in this market are AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd; Merck & Co. Inc.; Alcresta Therapeutics Inc.; Allergan; and AstraZeneca.
UK Cytomegalovirus Therapeutics Market Analysis
UK Cytomegalovirus Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A member of the Herpesviridae family with an envelope, the human herpesvirus 5 (HHV-5) is also referred to as cytomegalovirus. Around 40% to 100% of adults worldwide have experienced HHV-5 exposure at some point in their lifetime, making it a very common virus. A rise in the frequency of cytomegalovirus infection, investments in research & development, and the introduction of novel medicines are some of the reasons driving the growth of the market for cytomegalovirus therapeutics. Several Global pharmaceutical firms, including Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, Lion TCR, and others are active in this Cytomegalovirus Therapeutics market.
UK Dilated Cardiomyopathy Therapeutics Market Analysis
UK Dilated Cardiomyopathy Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The phrase "dilated cardiomyopathy" refers to conditions that affect the heart muscle and is regarded as a deadly cardiac condition. Reduced myocardial contractility and left and right ventricular dilatation are usually its defining characteristics. The potential driving force behind the DCM Therapeutics Market has been the rise in diagnostic alterations and symptom awareness, as well as declining dietary and lifestyle choices that have led to an increase in the occurrence of disease. The government is sponsoring research and development (R&D) projects to encourage scientists and pharmaceutical firms to create novel treatments. Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc. (J&J), Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vericel Corporation, and many others are key players in the market for cystic fibrosis (CF) therapeutics.
UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis
UK Duchenne Muscular Dystrophy (DMD) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A genetic condition known as Duchenne muscular dystrophy (DMD) is characterised by advancing muscle weakness and degeneration as a result of changes to a protein called dystrophin, which aids in maintaining healthy muscle cells. The market is expanding as a result of favourable government initiatives that provide appropriate reimbursement policies and promote target-specific treatments. Rapid urbanisation, better medical infrastructure, the emergence of product premiumization, and rising disposable incomes among the general populace are a few other drivers generating profitable growth potential in the industry. Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals, and many more are Global companies in the DMD Therapeutics market.
UK Fabry Disease Therapeutics Market Analysis
UK Fabry disease Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A lack of lysosomal hydrolase -galactosidase causes Fabry disease (FD), an X-linked inborn error of lysosomal storage disorder. A activity brought on by harmful variations in the GLA gene. The market for fabry disease drugs is growing rapidly as a result of increase in incidence and prevalence of fabry disease globally, increase in awareness about the disease globally, better diagnosis rates, improved access to treatment, development of new emerging therapies, orphan drug designations provided by regulatory bodies, increase in stratergic collaborations, rise in research and development activities and approval of promising pipeline products. Chiesi Farmaceutici SpA, Sanofi, Shire, Takeda Pharmaceutical Company Limited, Amicus Therapeutics, Inc., JCR Pharmaceuticals, Moderna are the key market players operating in global fabry disease Therapeutics Market.